First a message from our friends at The Oxford Club [sponsor]
Dear Reader,
The silicon chip reigned supreme for almost 70 years.
But now, thanks to a tiny company just 1/2500th the size of Nvidia, that era might be over forever.
As Microchip USA reports, this company’s patented wonder material “is reshaping power electronics, surpassing silicon with higher efficiency, faster switching, and superior thermal performance.”
Reshaping electronics might be the understatement of the year.
This wonder material just set two new world records.
And the stats are off the chart.
It’s up to 40% more energy-efficient than silicon…
With up to 20X faster processing speeds…
And 100X better performance!
If you’re looking for one stock that could rival the 35,600% gain Nvidia produced over the last 10 years, this stock might just be it.
It has the potential to become the most important company in the world by this time next year.
Yours in smart speculation,
Ryan Fitzwater, CEO
Monument Traders Alliance
P.S. Nvidia itself just partnered with the company. They want access to this tech immediately. And that could be very big for the tiny stock.
Hims vs. Novo: The GLP-1 Crackdown Rocking Stocks Today
If you judge “search volume” the way most trading desks do—what’s dominating headlines, trending tickers, and retail attention across major market feeds—today’s clear #1 story is the Hims & Hers (HIMS) vs. Novo Nordisk (NVO) GLP-1 crackdown/lawsuit saga.
Hims launched and then pulled a $49 compounded semaglutide-based pill after a rapid regulatory backlash; Novo responded with a patent infringement lawsuit, and the market instantly repriced both the upstart distribution model and the incumbents’ IP moat. Reuters framed it as a potential “tipping point” for a broader crackdown on compounded GLP-1s. Barron’s highlighted the same dynamic: Hims down sharply, Novo and Lilly up as copycat pressure eases.
This is the kind of “single story” active traders should take seriously because it hits multiple dimensions at once:
regulation and enforcement risk (FDA/HHS/DOJ),
IP and litigation,
revenue model durability,
and, crucially, positioning (who was long/short and why).
Below is the deep dive on what actually happened, why the tape reacted so hard, and how an active trader can build strategies around it—without pretending we know the lawsuit outcome or the next regulatory headline.
The GLP-1 Reckoning: Why Today’s HIMS/NVO Story Matters More Than a One-Day Move
1) What happened, in plain English (and why it’s “market-structural”)
The trigger: Hims & Hers—best known as a direct-to-consumer telehealth platform—briefly offered a deeply discounted $49 “Wegovy-like” compounded pill and then reversed course after swift pushback and regulatory scrutiny.
The escalation: Novo Nordisk filed a patent infringement lawsuit, seeking to halt sales of unapproved compounded drugs that Novo argues infringe its patents and to recover damages.
The market reaction:
Hims stock sold off sharply (double-digit %), and by the close Nasdaq highlighted the size/texture of the move: HIMS closed at $19.33, down 16.03%, with 143.5 million shares traded—about 688% above its 3-month average (18.2M).
Novo shares rose about 5% as investors interpreted the crackdown as supportive of the incumbent’s IP moat, and Reuters reported Lilly was steadier as well.
That’s not a normal “earnings miss” move. That’s a model risk repricing in real time.
2) Why this story is so searchable (and why traders should care)
There are three reasons this story is grabbing disproportionate attention today:
A) It combines consumer economics + regulation + investing
GLP-1s have become a cultural phenomenon—patients, insurers, employers, politicians, and investors all care. When a company appears to offer a “$49 version” of a blockbuster therapy, that crosses from finance into everyday life.
B) It changes the competitive map
The market has been debating whether compounded alternatives could meaningfully compress brand pricing power. A rapid crackdown narrative supports the opposite: incumbents may regain leverage.
Reuters explicitly noted analysts saw the lawsuit + unusually rapid FDA response as potential signals of a broader crackdown on compounded GLP-1s.
C) The price action was “loud”
Retail attention follows shock. A 16% down day on ~7x typical volume is exactly the kind of signal that sends a ticker to the top of watchlists and search bars.
3) The core debate: “distribution disruptor” vs. “IP moat wins”
Today’s tape is forcing a decision on two competing narratives:
Narrative 1: The disruptors win (price + access)
Hims’ bull case has included:
direct-to-consumer reach,
rapid product marketing and subscription economics,
and a broader thesis that U.S. healthcare distribution is inefficient and overpriced.
In that world, compounded GLP-1s (or other alternatives) could be a high-growth wedge.
Narrative 2: The incumbents win (regulation + IP + enforcement)
Novo’s (and Lilly’s) bull case is:
patents protect economics,
regulatory bodies ultimately enforce quality/safety,
and branded manufacturers can defend market share while shifting to new channels (including cash-pay/telehealth partnerships).
Reuters underscored that Novo sees this as a “tipping point,” describing a “growing chorus” saying “enough is enough” on compounding, and noting FDA signaled restriction on GLP-1 ingredients used in compounded drugs.
Active trader takeaway:
This isn’t a “who has the better product” story. It’s a who controls the rules of the game story. Those trade differently.
4) Why the move in HIMS was so violent: mechanics, not just emotion
A 16% drop on extraordinary volume typically reflects multiple forces stacking:
When a business line is suddenly questioned by regulators/lawsuits, markets demand a bigger discount rate. Even if the long-term outcome is fine, the path becomes uncertain—fund managers reduce exposure because they can’t model the next headline.
B) Positioning + crowded longs
High-growth “platform” names often accumulate a retail and momentum following. If the story changes abruptly, the unwind can be fast and reflexive.
C) Options and hedging flows
On big headline days, short-dated put buying and dealer hedging can amplify downside. You’ll often see:
the first drop,
a small bounce,
then a second leg lower as hedges reprice and weak hands exit.
The Nasdaq recap showing massive volume supports the view that this wasn’t a quiet institutional rebalance—it was broad, high-participation de-risking.
5) Why NVO (and often LLY) benefit: it’s not just “good news,” it’s less bad
Novo has faced its own challenges (pricing pressure narratives, competition, and the market’s shifting expectations), but today’s development is a rare “clear” positive: fewer copycat channels, stronger IP leverage, and potentially less near-term erosion from compounded alternatives. Reuters described it as easing competition on patented treatments if compounded GLP-1s face broader crackdown.
Active trader lens:
The best “incumbent rally” trades are often driven by:
relief (the threat is smaller),
and re-rating (the moat looks wider).
These can have follow-through if the narrative persists for more than one news cycle.
How active traders can approach this story
Strategy 1: Treat it as an “event regime,” not a one-day candle
The biggest mistake is assuming today’s move is the end of it. Legal/regulatory stories are usually multi-act:
headline shock
company responses
regulatory clarifications
additional lawsuits / settlements / enforcement actions
analyst revisions and guidance adjustments
Reuters itself framed the situation as potentially broader than Hims—more like an industry turning point.
Practical rule:
Trade smaller than usual until the story stabilizes. You want to survive the next headline.
Strategy 2: Build a “levels + headlines” playbook for HIMS
What you’re trading (really)
You’re trading regulatory narrative risk and business model perception, not just price levels.
A suggestive framework
If you’re bearish: wait for failed bounces (lower highs) and use defined-risk structures (put spreads) rather than chasing at lows.
If you’re looking for a bounce: demand proof the selling is exhausting:
volume contraction on down moves,
intraday reclaim of key VWAP/previous day levels,
and importantly, no new negative headline in the next 24–48 hours.
Remember the volume: 143.5M shares traded (vs. 18.2M average). That kind of washout can produce sharp rebounds—but only if the news stops getting worse.
Strategy 3: Trade the “moat beneficiaries” basket (NVO/LLY) with lower headline risk
For active traders who want exposure to the theme but less existential risk than HIMS:
NVO is the direct beneficiary of enforcing its IP (today’s catalyst was literally its lawsuit).
LLY is the other giant in the GLP-1 ecosystem, and often trades as a second beneficiary when enforcement pressures compounders.
Why this can be cleaner
Beneficiary trades often have:
clearer direction,
less “binary downside” from a single adverse ruling,
and more institutional sponsorship.
Strategy 4: Pair trade logic: “disruptor short vs. incumbent long”
If you’re an advanced active trader, this story sets up a classic relative-value concept:
Long NVO (or LLY)
Short HIMS (or use puts)
This expresses one view:
enforcement strengthens incumbents’ economics while weakening the disruptor’s wedge.
This is a narrative pair—it can reduce broader market beta because both legs sit inside the same macro universe (healthcare/GLP-1).
Strategy 5: Options structures that match the uncertainty
A) For HIMS (high headline risk)
Put spreads are often smarter than naked puts because implied volatility can be expensive after the initial shock.
Call spreads can be a way to play a bounce without overpaying for volatility.
B) For NVO/LLY (beneficiaries)
If you expect follow-through but want to limit premium, debit call spreads can express upside without the full cost of outright calls.
If you expect consolidation after a pop, put credit spreads (carefully sized) can monetize elevated volatility—only if you’re comfortable owning via assignment risk (many aren’t).
Strategy 6: Calendar awareness: don’t ignore macro this week
Even though this is a single-name story, the overall market is heading into major data catalysts (jobs/CPI this week), and risk-on/risk-off flows can swamp single-name trades at the margin.
The biggest trap:
you’re right on the HIMS/NVO narrative,
but the market sells everything growth (or buys everything defensively),
and your timing gets wrecked.
So keep position sizes aligned with the week’s volatility.
What to watch next (the “active trader checklist”)
For HIMS:
Any further statements about compounded GLP-1 offerings beyond the pulled pill
DOJ/agency updates or language that suggests broader enforcement
Analyst revisions (particularly around revenue mix and forward guidance)
Volume pattern: does it normalize or stay elevated?
For NVO:
Any new legal filings or escalation of the case
Commentary about cash-pay channels and demand elasticity
Whether the stock holds gains (a “hold” is often more important than the first pop)
For LLY:
Whether it trades as a beneficiary (relative strength vs. broader market)
Any competitive updates around oral GLP-1 timelines (the market will reprice that quickly)
The bottom line for active traders
Today’s biggest story isn’t “HIMS down” or “NVO up.” It’s the market repricing a single question:
Can the “cheap access via compounding” model survive sustained enforcement and IP litigation—at scale?
Reuters suggests the market is treating this as a broader crackdown moment, not a one-off dispute. Nasdaq’s volume data shows traders treated it as a major event, not a normal red day.
For active traders, the edge is not predicting the court outcome. The edge is:
recognizing event regimes,
trading defined risk,
and exploiting dispersion (the gap between winners and losers) while the rest of the market chops.
Editorial Disclaimer
This commentary is for informational and educational purposes only and does not constitute investment advice. All market strategies involve risk, and past performance is not indicative of future results. Readers should conduct their own analysis or consult a licensed financial professional before making investment decisions.